Yahoo Web Search

Search results

1. • Sarepta Therapeutics Inc [SRPT] Shares Fall Approximately

     Knox Daily· 12 hours ago

     Upon closing the transaction, the insider’s holdings decreased to 15,000 shares, worth approximately $2.9 million. As published in a research note from Oppenheimer on May 14, 2024, Sarepta Therapeutics ...

2. • 

     Implied Volatility Surging for Sarepta (SRPT) Stock Options

     Zacks via Yahoo Finance· 3 hours ago

     Investors in Sarepta Therapeutics, Inc. SRPT need to pay close attention to the stock based on moves...

3. • Decoding Sarepta Therapeutics's Options Activity: What's the Big Picture? - Sarepta Therapeutics...

     Benzinga· 3 hours ago

     Loading... Loading... Benzinga's options scanner has just identified more than 10 option transactions on Sarepta Therapeutics SRPT , with a cumulative value of $1,406,765.

4. • Sarepta Therapeutics (NASDAQ:SRPT) PT Raised to $179.00

     ETF DAILY NEWS· 6 days ago

     Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) had its target price hoisted by Mizuho from $145.00 to $179.00 in a report issued on Friday, Benzinga reports. The firm ...

5. • 10 Health Care Stocks With Whale Alerts In Today's Session - AbbVie (NYSE:ABBV), Bristol-Myers...

     Benzinga· 1 hour ago

     Date Strike Price Total Trade Price Open Interest Volume PFE CALL SWEEP BULLISH 05/31/24 $29.00 $50.3K 6.8K 8.2K SRPT CALL TRADE BULLISH 06/21/24 $110.00 $1.3 million 211 ...

6. • 

     The 2030 Millionaire's Club: 3 Biotech Stocks to Buy Now

     InvestorPlace· 1 day ago

     With the interest cuts coming up, it’s an ideal time to consider loading up on the top biotech...

7. • 

     Dyne (DYN) Soars 28% on New Data From Muscle Disease Studies

     Zacks via Yahoo Finance· 3 days ago

     Dyne (DYN) gains 28% after reporting positive new data from two separate ongoing mid to late-stage...

8. • 

     Jim Cramer: This Industrial Stock Is Doing 'Very Well'; Here's His Take On Palantir - Lazard...

     Benzinga· 2 days ago

     On CNBC's “Mad Money Lightning Round,” Jim Cramer said he likes Enbridge Inc. ENB. On May 10,...

9. • 

     Why This Biotech Just Launched — Again — After Its 166% Run

     Investor's Business Daily· 4 days ago

     Dyne studied drugs it calls DYNE-101 and DYNE-251 in patients with myotonic dystrophy type 1 and...